Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Obes Sci Pract
Autori principali: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Short Communications
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://ncbi.nlm.nih.gov/pubmed/32874678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/osp4.420
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi